By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Proterris 

Avenida da República

Oeiras  Lisbon  2980-09-01   Portugal
Phone: n/a Fax: n/a


SEARCH JOBS

Proterris is a clinical-development stage company focused on therapeutic applications of low-dose carbon monoxide (CO). Leveraging CO’s demonstrated anti-fibrotic, anti-inflammatory and cytoprotective properties, Proterris is initially focused on developing CO for delayed graft function (DGF) in renal transplant recipients and idiopathic pulmonary fibrosis (IPF). Other indications, including pulmonary arterial hypertension (PAH) and acute respiratory distress syndrome (ARDS), are also being developed by the National Institutes of Health (NIH). CO has broad potential to significantly impact the lives of millions of patients suffering from a wide variety of both acute and chronic diseases.

LEADERSHIP:

Founders: Jeffrey Wager and Joseph Wager

Founder and CEO: Jeffrey Wager

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Private

Web Site: Proterris
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->